SCHEMBL17544632

SCHEMBL17544632

COc1ccc(CC(C)C)c[n+]1[O-]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
SLC6A4 P31645 1/20 0.34
CXCR1 P25024 2/20 0.34
CXCR2 P25025 2/20 0.34
FAAH O00519 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB2 P47870 1/20 0.33
IDH1 O75874 1/20 0.33
MGLL Q99685 1/20 0.33
LMNA P02545 1/20 0.33
ALB P02768 1/20 0.33
ESR1 P03372 1/20 0.33
ALOX5 P09917 1/20 0.33
RARB P10826 1/20 0.33
CYP2C9 P11712 1/20 0.33
ADRB3 P13945 1/20 0.33
NFKB1 P19838 1/20 0.33
PTGS1 P23219 1/20 0.33
HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17683832 0.79 CXCR1 (0.41) SLC6A4CXCR1CXCR2FAAHGABRA1
SCHEMBL2223779 0.78 IDH1 (0.35) IDH1
SCHEMBL15695537 0.74 ALDH1A1 (0.39) ALDH1A1CXCR1CXCR2FAAHGABRA1
SCHEMBL13291152 0.67 GAA (0.38) IDH1
SCHEMBL104850 0.66 SLC6A4 (0.69) SLC6A4
SCHEMBL1131597 0.66 PTGS1 (0.56) ALDH1A1CXCR1CXCR2FAAHGABRA1
Ammonia Solution, Strong SCHEMBL8170665 0.65 SLC6A4 (0.67) SLC6A4
SCHEMBL14417133 0.64 SLC6A4 (0.34) ALDH1A1SLC6A4CXCR1CXCR2FAAH
SCHEMBL13741192 0.64 GPR84 (0.46)
SCHEMBL5174938 0.63 PTGS1 (0.54) ALDH1A1CXCR1CXCR2FAAHGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802941-B2 Compounds and methods for inhibiting histone demethylases GILEAD SCIENCES, INC. (US) 2017-10-31 US disclosed
US-9802941-B2 Compounds and methods for inhibiting histone demethylases GILEAD SCIENCES, INC. (US) 2017-10-31 US disclosed
EP-3186238-A1 COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES GILEAD SCIENCES, INC. (US) 2017-07-05 EP disclosed
US-20160102096-A1 COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES EPITHERAPEUTICS APS 2016-04-14 US disclosed
WO-2016033169-A1 COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES EPITHERAPEUTICS APS (US) 2016-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102096-A1 COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES PHF8, KDM3A, PHF2 ALDH1A1 802/4885SLC6A4 4608/4885CXCR1 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.